Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep;45(3):210-9.
doi: 10.4143/crt.2013.45.3.210. Epub 2013 Sep 30.

Prognostic role of interleukin-6, interleukin-8, and leptin levels according to breast cancer subtype

Young Ae Cho  1 , Mi-Kyung Sung, Jee-Young Yeon, Jungsil Ro, Jeongseon Kim
Affiliations

Prognostic role of interleukin-6, interleukin-8, and leptin levels according to breast cancer subtype

Young Ae Cho et al. Cancer Res Treat. 2013 Sep.

Abstract

Purpose: Inflammation within the tumor microenvironment has been reported to show an association with poor prognosis in breast cancer. However, the associations may differ according to breast cancer subtype. In this study, we investigated the association between inflammation-related markers and breast cancer recurrence according to patients' tumor subtypes.

Materials and methods: This prospective study included 240 patients who underwent surgery for management of newly diagnosed breast cancer. Levels of inflammation-related markers (interleukin [IL]-1β, IL-6, IL-8, monocyte chemoattractant protein-1 [MCP-1], leptin, and adiponectin) were measured at diagnosis, and the associations between these markers and breast cancer recurrence during a six-year follow-up period were examined using the Kaplan-Meier statistical method.

Results: Overall, inflammation-related markers showed no association with breast cancer recurrence. However, when data were stratified by tumor subtype, higher levels of some mediators showed an association with poor prognosis among patients with particular subtypes. Compared to patients without recurrence, patients with recurrence had higher levels of circulating IL-6 (p=0.024) and IL-8 (p=0.016) only among those with HER2(-) tumors and had higher levels of leptin (p=0.034) only among those with estrogen receptor (ER)(+)/progesterone receptor (PR)(+) tumors. Results of survival analyses revealed an association of high levels of IL-6 (p=0.016) and IL-8 (p=0.022) with poor recurrence-free survival in patients with HER2(-) tumors. In addition, higher leptin levels indicated shorter recurrence-free survival time only among patients with ER(+)/PR(+) tumors (p=0.022).

Conclusion: We found that certain cytokines could have a differential prognostic impact on breast cancer recurrence according to breast cancer subtype. Conduct of additional large studies will be required in order to elucidate the precise roles of these cytokines in breast cancer progression.

Keywords: Breast neoplasms; Cytokines; Estrogen receptors; HER2; Progesterone receptors; Recurrence.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest relevant to this article was not reported.

Figures

Fig. 1
Fig. 1
Effect of interleukin 6 (IL-6) on breast cancer recurrence-free survival according to HER2 status: (A) HER2 positive and (B) HER2 negative.
Fig. 2
Fig. 2
Effect of interleukin 8 (IL-8) on breast cancer recurrence-free survival according to HER2 status: (A) HER2 positive and (B) HER2 negative.
Fig. 3
Fig. 3
Effect of leptin on breast cancer recurrence-free survival according to estrogen receptor (ER)/progesterone receptor (PR) status: (A) ER/PR positive and (B) ER/PR negative.
See this image and copyright information in PMC

References

    1. Goldberg JE, Schwertfeger KL. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets. 2010;11:1133–1146. - PubMed
    1. Gilbert CA, Slingerland JM. Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Annu Rev Med. 2013;64:45–57. - PubMed
    1. Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev. 2006;17:325–337. - PubMed
    1. Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer. 2008;8:887–899. - PubMed
    1. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7:4–13. - PMC - PubMed

LinkOut - more resources